Marina joined Nouscom in 2016 as the Chief Operating Officer from Versant Ventures where she was an Operating Principal. Prior to Versant, Marina was at Novartis Pharma in Basel in various senior [...]
Elisa joined Okairos in 2010 as the company’s Clinical Director. Prior to Okairos, she was a Scientist at IRBM / Merck since 1992, where she worked first on Hepatitis C infection and immunity and [...]
Tiffany has 15 years of experience in finance including investments, global treasury, and investor relations. Prior to joining Nouscom in 2019, she held leadership roles with a U.S. based Fortune [...]
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.